Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
复制标题
DOI：
10.1038/s41598-019-52944-6
复制
发表时间：
2019-11-13
影响因子：
4.6
通讯作者：
Shirabe, Ken
中科院分区：
文献类型：
--
作者：
Kurozumi, Sasagu;Inoue, Kenichi;Shirabe, Ken
几项正在进行的临床试验正在研究使用程序性细胞死亡蛋白-1和程序性死亡配体1（PD-L1）抑制剂的免疫靶向治疗三阴性乳腺癌。然而，PD-L1表达在HER 2阳性乳腺癌中的作用仍不清楚。我们研究了PD-L1表达在HER 2阳性乳腺癌中的临床病理学效用。队列A包括248例浸润性乳腺癌患者（所有亚型）。队列B包括126例接受新辅助化疗（NAC）联合曲妥珠单抗治疗的HER 2阳性患者。研究肿瘤细胞PD-L1表达与病理完全缓解（pCR）及预后等临床病理因素的关系。在队列A中，8.1%的患者为PD-L1阳性; PD-L1阳性与高度肿瘤浸润淋巴细胞（TIL）、雌激素受体阴性、孕激素受体阴性和高组织学分级相关。在队列B中，17.5%的患者为PD-L1阳性; PD-L1阳性与高程度的TIL和高丰度的CD 8阳性TIL显著相关。pCR率与TIL和PD-L1表达有关。在PD-L1阴性患者中，高CD 8阳性TIL与显著更好的预后相关。总之，17.5%的HER 2阳性患者为PD-L1阳性。在HER 2阳性乳腺癌患者中，PD-L1表达与曲妥珠单抗对NAC的应答相关。
Several ongoing clinical trials are investigating the use of immuno-targeting therapy with programmed cell death protein-1 and programmed death-ligand 1 (PD-L1) inhibitors for triple-negative breast cancer. However, the role of PD-L1 expression in HER2-positive breast cancer remains unclear. We investigated the clinicopathological utility of PD-L1 expression in HER2-positive breast cancer. Cohort A included 248 patients with invasive breast cancer (all subtypes). Cohort B included 126 HER2-positive patients who received neoadjuvant chemotherapy (NAC) concomitant with trastuzumab. The relationship of PD-L1 expression on the cancer cells with clinicopathological factors including pathological complete response (pCR) and prognosis was investigated. In cohort A, 8.1% patients were PD-L1-positive; PD-L1 positivity showed a correlation with high degree of tumor-infiltrating lymphocytes (TILs), estrogen receptor negativity, progesterone receptor negativity, and high histological grade. In cohort B, 17.5% patients were PD-L1-positive; PD-L1 positivity showed a significant correlation with high degree of TILs and high abundance of CD8-positive TILs. The pCR rates were related to TILs and PD-L1 expression. Among PD-L1-negative patients, high CD8-positive TILs were associated with significantly better prognosis. In conclusion, 17.5% of HER2-positive type patients were PD-L1-positive. PD-L1 expression was associated with response to NAC with trastuzumab in patients with HER2-positive breast cancer.